A new model for in vitro testing of vitreous substitute candidates by Barth, Henrik et al.
BASIC SCIENCE
A new model for in vitro testing of vitreous substitute candidates
Henrik Barth & Sven Crafoord & Timothy M. O’Shea &
Christopher D. Pritchard & Robert Langer &
Fredrik Ghosh
Received: 6 April 2014 /Revised: 11 June 2014 /Accepted: 26 June 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract
Purpose To describe a new model for in vitro assessment of
novel vitreous substitute candidates.
Methods The biological impact of three vitreous substitute
candidates was explored in a retinal explant culture model; a
polyalkylimide hydrogel (Bio-Alcamid®), a two component
hydrogel of 20 wt.% poly (ethylene glycol) in phosphate
buffered saline (PEG) and a cross-linked sodium hyaluronic
acid hydrogel (Healaflow®). The gels where applied to
explanted adult rat retinas and then kept in culture for 2, 5
and 10 days. Gel-exposed explants were compared with ex-
plants incubated under standard tissue culture conditions.
Cryosections of the specimens were stained with hematoxylin
and eosin, immunohistochemical markers (GFAP, Vimentin,
Neurofilament 160, PKC, Rhodopsin) and TUNEL.
Results Explants kept under standard conditions as well as
PEG-exposed explants displayed disruption of retinal layers
with moderate pyknosis of all neurons. They also displayed
moderate labeling of apoptotic cells. Bio-Alcamid®-exposed
explants displayed severe thinning and disruption of retinal
layers with massive cell death. Healaflow®-treated explants
displayed normal retinal lamination with significantly better
preservation of retinal neurons compared with control
specimens, and almost no signs of apoptosis. Retinas exposed
to Healaflow® and retinas kept under standard conditions
showed variable labeling of GFAP with generally low expres-
sion and some areas of upregulation. PEG-exposed retinas
showed increased GFAP labeling and Bio-Alcamid®-exposed
retinas showed sparse labeling of GFAP.
Conclusions Research into novel vitreous substitutes has im-
portant implications for bothmedical and surgical vitreoretinal
disease. The in vitro model presented here provides a method
of biocompatibility testing prior to more costly and cumber-
some in vivo experiments. The explant culture system im-
poses reactions within the retina including disruption of
layers, cell death and gliosis, and the progression of these
reactions can be used for comparison of vitreous substitute
candidates. Bio-Alcamid® had strong adverse effects on the
retina which is consistent with results of prior in vivo trials.
PEG gel elicits reactions similar to the control retinas whereas
Healaflow® shows protection from culture-induced trauma
indicating favorable biocompatibility.
Keywords Vitreous substitute . Immunohistochemistry .
Retinal culture . Vitreoretinal surgery . Hyaluronic acid .
Polyethylene oxide . Polyal kylimide
Introduction
Vitrectomy is a common procedure for several eye disorders
capable of severely impacting the vision of affected patients
and has an important role in the treatment of conditions such
as rhegmatogenous retinal detachment, severe diabetic reti-
nopathy, penetrating ocular trauma, macular holes and
epiretinal membranes. The removal of vitreous tissue during
vitreoretinal surgery mandates its replacement, either in the
form of water or various tamponading agents. The compounds
currently in widespread clinical use such as balanced salt
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solutions, gases, silicon oils and perflourocarbon liquids all
have considerable disadvantages, with complications such as
cataract formation, uveitis, increased intraocular pressure [1]
and cytotoxicity [2, 3]. Further, current tamponading agents
are either resorbed spontaneously after a few weeks or are not
suitable for long-term use [4–9], and may require strict body
positioning postoperatively.
The search for improved vitreous substitutes has been
ongoing since the early days of the 20th century [10]. Early
attempts were made to transplant animal and human vitreous
[11] and investigations have been made into numerous semi-
synthetic [12–14] and synthetic [15] molecules, although few
of them have reached a clinical setting and none have fulfilled
the requirements for long-term biocompatibility.
Traditionally the interactions of vitreous substitutes with
eye tissues have been studied in various animal models in
vivo. Such trials are, however, costly, time consuming and
might be considered ethically problematic. In some cases
in vivo experiments have been precluded by preclinical
toxicological assays, mainly targeting apoptosis in cultures
of cells from tissues outside the eye [16, 17], isolated retinal
pigment epithelium (RPE) cells [18, 19] or dissociated cells
from embryonal retinas [20]. The validity of these findings in
relation to a clinical setting is, however, unclear since they
represent a large transitional step regarding the impact on the
adult neuroretinal sheet [21]. Therefore, a means to investigate
the biological impact of vitreous substitutes more similar to
the in vivo situation is desirable.
For this paper we wanted to explore a novel in vitro model
for investigating the biological impact of vitreous substitutes
on the neuroretina. To this end we have used the well-
established retinal explant model to study three polymer
hydrogels of different chemical composition that theoretically
may be considered as potential vitreous substitutes; 1) Cross-
linked hyaluronic acid (Healaflow®), clinically used in glau-
coma surgery [22, 23]; 2) Poly (ethylene glycol) (PEG),
widely used in different biochemical applications [24, 25];
and, 3) Polyalkylimide (Bio-Alcamid®), clinically used in
reconstructive surgery [26–29].
Materials and methods
Three vitreous substitute candidates were investigated in the
retinal explant culture model: a cross-linked sodium
hyaluronic acid (22,5 mg/ml) hydrogel (Healaflow®); a two
component hydrogel of 20 wt.% poly (ethylene glycol) in
phosphate buffered saline (PEG) and a polyalkylimide hydro-
gel (Bio-Alcamid®). The gels where applied to explanted
adult rat retinas and then kept in culture for 2, 5, and 10 days
in vitro (DIV). Gel-exposed explants were compared with
explants incubated under standard conditions (medium only).
Cryosections of the specimens were stained with hematoxylin
and eosin, immunohistochemical markers (GFAP, Vimentin,
PKC, NF160, Rhodopsin) and TUNEL.
Animals
Retinas from adult Sprague–Dawley rats were used. All pro-
ceedings and animal treatment were in accordance with the
guidelines and requirements of the government committee on
animal experimentation at Lund University and with the As-
sociation for Research in Vision and Ophthalmology (ARVO)
statement on the use of animals in ophthalmic and vision
research.
Gels
Healaflow® (Anteis S.A., Plan Les Ouates, Switzerland) is a
commercially available translucent hydrogel, clinically used
in glaucoma filtering surgery as a space-filler and to limit
postoperative fibrosis [22, 23]. The hydrogel consists of over
97% water, sodium hyaluronic acid (22.5 mg/ml) of non-
animal origin cross-linked with BDDE (1.4-Butanediol
diglycidyl ether), and phosphate- and NaCl-salts to maintain
a physiological pH (7.0) and osmolarity (305 mOsm/kg). The
estimated specific gravity is circa 1.03, and the refractive
index i=1.341.
A custom made two component cross-linked hydrogel
(PEG) consisting of 20 wt.% poly (ethylene glycol) in phos-
phate buffered saline (PBS) was prepared by mixing PEGDA
in PBS into ETTMP-1300 in PBS [30]. PEG is a synthetic
water-soluble polymer approved by the FDA for biomedical
use in different applications including injectable hydrogels. It
has been investigated for use in intravitreal drug delivery,
repair of scleral incisions and the sealing of retinal breaks in
retinal detachment surgery [24, 25].
Bio-Alcamid® (Polymekon, Brindisi, Italy) is a commer-
cially available clear hydrogel in clinical use as tissue filler for
plastic and reconstructive surgery, mainly for lipoatrophic and
posttraumatic conditions. The hydrogel consists of approxi-
mately 4% reticulated polyalkylimide and approximately 96%
non-pyrogenic water (pH 6.9), it contains no free monomers
and is considered physically and chemically stable [29]. In
vivo a collagen capsule surrounding the implanted Bio-
Alcamid® is formed.
Tissue handling and culture procedure (Fig. 1)
The rats were euthanized with CO2 with subsequent de-
capitation, enucleation and immediate immersion of the eyes
in an ice-cold CO2-independent medium (Gibco, Paisley,
UK). The neuroretinas were dissected from the retinal pigment
epithelium (RPE) and the vitreous with fine forceps, and either
half or the entire neuroretinas were subsequently explanted on
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to culture plate inserts (Millicell Isopore-PCF 0.4 μm, 30mm;
Millipore, Billerica, ME) with the photoreceptor layer against
the membrane, and covered by 50–100 μl gel (Healaflow®,
PEG, or Bio-Alcamid®) depending on the size of the explant.
The explants were cultured in 2 ml of Dulbecco’s modified
Eagle’s medium (DMEM)/F12 medium–l-glutamine (Gibco)
supplemented with 10% fetal calf serum, with a drop of
enriched medium applied directly onto the gels to ensure
saturation. The cultures were also supplemented with
2 mM l-glutamine, 100 U/ml penicillin and 100 ng/ml strep-
tomycin (Sigma-Aldrich, St Louis, MO), and the retinas were
kept at 37 °C at 95% humidity and 5% CO2. Four explants in
each group (standard conditions, Healaflow®, PEG, and Bio-
Alcamid®) were kept in culture for 2 days and six explants in
each group were kept for 5 or 10 days, with exchange of half
the culture medium after 3, 5, 7 and 9 days. No exchange of
gel was made during the change of medium.
Immunohisto chemistry
In preparation for further histological studies the explants
were fixed for 1 h in 4% formalin (pH 7.3) in 0.1 M Sørensen
phosphate buffer (PB). The specimens were then washed with
0.1 M Sørensen PB; this was repeated with the same solution
containing sucrose of increasing concentrations (5–25 %).
Specimens were sectioned to 12 μm on a cryostat and every
tenth slide was stained with hematoxylin and eosin according
to standard procedures.
For immunohistochemical staining sections were washed
at room temperature with 0.1 M of sodium PBS (pH 7.2) with
0.1% Triton X–100 (PBS/Triton), and thereafter incubated
overnight at 4 °C with antibodies against the following anti-
gens; Rhodopsin [rod photoreceptors] (Rho4D2, a kind gift
from Prof. R.S. Molday, Vancouver, Canada; monoclonal,
diluted 1:100), phospho-protein kinase C [PKC, rod bipolar
cells] (K01107M; Cell Signaling, USA; diluted 1:200), Neu-
rofilament 160 KDa [NF1 60, ganglion and horizontal cells]
(clone NN18; Sigma, St. Louis, MO, USA; diluted 1:500),
glial fibrillary acidic protein [GFAP, activated Müller cells]
(clone G-A-5; Millipore, Sundbyberg, Sweden; diluted 1:200
with PBS/Triton with 1% bovine serum albumin) and
vimentin [Müller cells] (Chemicon, USA; 1: 500). After incu-
bation with the antibodies and rinse with PBS/Triton the slides
were incubated with fluorescein isothiocyanate (FITC)-conju-
gated antibodies (Sigma-Aldrich, St. Louis, MO, USA) for
45 min, rinsed and mounted in an anti-fading mounting media
(Vectashield, Vector laboratories, Inc., Burlingame, CA,
USA). Negative controls were obtained by performing the
same procedure as above but without any primary antibodies.
Antibodies are summarized in Table I. For identification of
apoptotic cells a commercial terminal transferase-mediated
dUTP nick-end labeling (TUNEL) assay system with
fluorescein-conjugated dUTP (Boehringer Mannheim, Mann-




All gels (Healaflow®, PEG and Bio-Alcamid®) could suc-
cessfully be applied to the explanted retinal tissue.
Healaflow® and PEG formed even films over the retinal
explants whereas Bio-Alcamid® retained a thick, uneven
Fig. 1 Schematic overview of the
retinal explant culture system
with the vitreous substitute
candidate
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texture that did not cover the explants completely even after a
prolonged time. The PEG gel was found to benefit from a
20 min incubation time prior to administration of the medium,
allowing for some gelation and preventing dissolution. The
gels remained translucent and could be visualized at every
exchange of the medium and were confirmed to be macro-
scopically saturated with the colored medium by means of
visual inspection. Two of the explant-cultures suffered infec-
tion and were excluded from further analysis.
Cytoarchitecture and cell death (Fig. 2)
After two DIV hematoxylin- and eosin-stained sec-
tions of explants kept under control conditions as well
as PEG-exposed explants displayed an abnormal retinal
lamination with a wavy appearance of the outer nuclear
layer (ONL). The ONL also displayed variable thickness,
displacement towards the inner retina and moderate
pyknosis. Inner retinal layers displayed some variability
in total thickness and moderate pyknosis. Healaflow®-
treated explants showed almost normal retinal lamination
with significantly better preservation of retinal neurons
compared with control specimens, whereas Bio-
Alcamid®-exposed explants displayed a highly variable
cytoarchitecture with severe thinning and disruption of all
retinal layers in most parts, and a less disrupted structure in
minor areas. TUNEL labeling at 2 DIV demonstrated no or
almost no apoptotic cells with explants kept under control
conditions, with Healaflow® and with PEG, and some apo-
ptosis with explants cultured with Bio-Alcamid®. After 5 and
10 DIV a progressive increase in pyknosis and laminar dis-
ruption was seen in all groups. Retinas kept under standard
conditions, and especially with Healaflow®, exhibited less
pyknosis and laminar disruption than those treated with PEG
and Bio-Alcamid®. TUNEL labeling of 5 DIV explants kept
under control conditions and those subjected to PEG
displayed moderate signs of apoptosis. Healaflow®-treated
retinas showed almost no TUNEL labeling whereas explants
treated with Bio-Alcamid® displayed massive cell death. At
10 DIV intense TUNEL labeling was observed in explants
cultured under standard conditions, low labeling with
Healaflow®-treatment and very low labeling in the PEG-
and Bio-Alcamid®-treated cultures.
Rod photoreceptors (Fig. 3)
Rhodopsin-labeled photoreceptor cells in standard cultures
displayed high intensity labeling of the outer segments (OS)
and in the outer plexiform layer (OPL), with mild intensity
labeling present in the ONL. Similar patterns of labeling were
seen at 2 and 5 DIV. At 10 DIV stronger labeling was seen in
the ONL. The Rhodopsin labeling pattern of Healaflow®- and
PEG-exposed explants was comparable to the standard
Table I Specification of immounohistochemical markers
-
Fig. 2 Cryosections of rat retina explants at 2, 5 or 10 days in vitro
(DIV) cultured with standard conditions (CTRL), Healaflow® (HF),
PEG-gel (PEG) and Bio-Alcamid® (BA). Hematoxylin and eosin
staining (top rows), and TUNEL staining (bottom rows). Abbreviations:
inner nuclear layer (INL), outer nuclear layer (ONL). Scale bar=25 μm
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control. Bio-Alcamid® explants displayed intense labeling of
the entire ONL already at 2 DIV.
Inner retinal cells (Fig. 4)
PKC labeling for rod bipolar cells at 2 DIV displayed a
high variability with the most intense labeling towards the
peripheral edge of the control explants. In 5 DIV specimens
only a few PKC-labeled cell bodies were found whereas 10
DIV specimens did not show any remaining rod bipolar cells.
In Healaflow®-treated specimens at 2 DIVa few PKC-labeled
rod bipolar cells were found, but in older explants no such
cells were found. PEG and Bio-Alcamid® explants did not
display any PKC-labeled rod bipolar cells.
Neurofilament 160-labeled ganglion cells were seen in all
retinal cultures with no clear differences between the different
tested gels. No difference was observed between different
incubation times.
Müller cells (Fig. 5)
GFAP labeling, indicative of Müller cell activation,
showed very low intensity in most parts of the control retinas
at 2 DIV but intense labeling was present in astrocytes located
in the innermost retina. A generally low labeling intensity was
seen at 5 DIV with some areas of moderate to high labeling of
Müller cells (shown in Fig. 4). At 10 DIV some areas of
moderate labeling was seen with mostly fragmentary labeling
having a tortuous appearance of the Müller cell fibers.
Healaflow®-subjected retinas displayed patterns similar to
those of the control retinas at all timepoints, although there
Fig. 3 Cryosections of rat retina explants at 2, 5 or 10 days in vitro
(DIV) cultured with: standard conditions (CTRL), Healaflow® (HF),
PEG-gel (PEG) and Bio-Alcamid® (BA). Immunohistochemical staining
for Rhodopsin. Abbreviations: inner nuclear layer (INL), outer nuclear
layer (ONL). Scale bar=25 μm
Fig. 4 Cryosections of rat retina explants at 2, 5 or 10 days in vitro
(DIV) cultured with: standard conditions (CTRL), Healaflow® (HF),
PEG-gel (PEG) and Bio-Alcamid® (BA). Immunohistochemical
staining: a PKCpan; b Neurofilament 160. Abbreviations: inner nuclear
layer (INL), outer nuclear layer (ONL). Scale bar=12.5 μm
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was a tendency towards a slightly lower labeling intensity at 5
DIV.
The retinas exposed to PEG and Bio-Alcamid® displayed a
high labeling intensity in the inner retina with labeled Müller
cell fibers occasionally reaching the ONL at 2 DIV. After 5
DIVmoderate, variable expression both in the inner retina and
in fibrils was exhibited on the PEG exposure. Bio-Alcamid®-
exposed retinas exhibited low labeling intensity, almost ex-
clusively in the inner retina. At 10 DIV cultures with PEG
showed moderate, variable expression and those cultured with
Bio-Alcamid® displayed only weak labeling present in the
inner retina.
Vimentin labeling of Müller cell cytoskeletons was present
in fibers through the inner parts of the retina, in some areas
through to the ONL, with some labeling in the innermost
retina. No significant differences were seen between the dif-
ferent groups but increased hypertrophy and disorganization
of Müller cell fibers was seen over time with the labeling
pattern appearing almost granular at later time points.
Discussion
Summary
In this study a new in vitro model for evaluating the
effect of potential vitreous substitutes on adult
neuroretinal sheets was explored. Three potential candi-
dates were evaluated and compared to retinal explants
cultured under standard conditions. Clear differences
were seen between the groups with similar effects ob-
served in explants cultured under standard conditions and
with Healaflow®, and more degenerative findings in
cultures with PEG and, particularly, Bio-Alcamid®. The
relative degenerative morphological and immunohisto-
chemical changes for the different gels compared to
standard conditions are summarized as qualitative com-
pound scores in Table 2.
The in vitro model
Research into novel vitreous substitutes has important impli-
cations for both medical and surgical vitreoretinal disease. An
in vitro assay analysed using immunohistochemistry and
morphological stainings can determine the biocompatibility
and safety of potential vitreous substitutes. This may provide
better predictions of the effects of novel substances on the
retina than the traditional, more simplistic in vitro assays
currently in use [16–19, 21, 31].
The in vitro model presented here provides a method of
biocompatibility testing prior to more costly and cumbersome
in vivo experiments [20]. In retinal explant cultures under
standard conditions there are several well-characterized reac-
tions easily observable as early as 3 or 4 DIV [32–34]. These
reactions include gliosis and neuroretinal degeneration and
can be visualized by GFAP upregulation, disruption of the
cell layers and the labeling of apoptotic cells. Using these
reactions elicited by the explant culture system under standard
conditions and comparing them to different vitreous substitute
candidates indicates the biocompatibility of the substances
in vivo.
Our previous results and our hypothesis
The vitreous is often simplistically seen as a mere space filler
inside the eye bulb. There is, however, evidence of a more
intricate and purposeful composition [10] with important
physiological implications on the micro-milieu of the retina
including the upkeep of salt and nutrient gradients, physical
support and more [35, 36]. An ideal vitreous substitute would
replicate these influences on the neuroretina and surrounding
tissues as well as provide a tamponading effect after vitrecto-
my [10].
In two recent papers our group investigated two promising
potential intravitreal substitutes in an in vivo rabbit model:
Polyalkylimide (Bio-Alcamid®) [37] and a poly (ethylene
glycol) (PEG) hydrogel [38].
Bio-Alcamid® is a translucent hydrogel with high biocom-
patibility [26, 27] used in plastic surgery and in clinical use
forms a surrounding collagen capsule giving it a degree of
isolation from the surrounding tissue [28]. The synthetic poly-
mer hydrogel PEG is used in different biomedical application,
has been tested for intravitreal administration of drugs [24, 39]
and is FDA approved for use intravitreally. The in vivo trials
showed favorable biocompatibility but inadequate stability
in vivo using PEG where the substance was largely tolerated
with minor changes in retinal cytoarchitecture and GFAP-
upregulation, and minor electrophysiological changes [38].
On the other hand, Bio-Alcamid® displayed suitable physical
properties but caused severe functional and morphological
retinal damagewith increased GFAP expression and cell death
(TUNEL) [37].
The use of derivates of sodium hyaluronic acid in
vitreoretinal surgery predates their ubiquitous use in cata-
ract and anterior segment surgery [12, 14, 40–42], but their
use in a clinical setting has been limited mainly due to
concern about short term side effects and retention time
[41, 43]. Healaflow® is a commercially available com-
pound consisting of a cross-linked sodium hyaluronic acid
Fig. 5 Cryosections of rat retina explants at 2, 5 or 10 days in vitro
(DIV) cultured with: standard conditions (CTRL), Healaflow® (HF),
PEG-gel (PEG) and Bio-Alcamid® (BA). Immunohistochemical
staining: a GFAP; b Vimentin. Abbreviations: inner nuclear layer (INL),
outer nuclear layer (ONL). Scale bar=12,5
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hydrogel and is FDA approved for use in glaucoma surgery
[22, 23]. The composition of Healaflow® is akin to natural
vitreous: a reinforced hydrogel of hyaluronic acid with
similar physical properties and thus considered a plausible
candidate for vitreous substitution.
In vivo vs. in vitro: our earlier results and others
It seems to us that a good correlation exists between the results
of this in vitro explant culture system and earlier results for all
the tested substances.
In this setting retinal explants cultured with Healaflow®
compare very well to specimens cultured under standard
conditions and even seem to lessen the trauma caused by the
culture process. This is consistent with the excellent biocom-
patibility of hyaluronic acid seen in other studies [18, 19].
Hyaluronic acid is one of the main constituents of natural
vitreous and is consistently well-tolerated in different biomed-
ical applications. Healaflow® may exert a protective effect
from culture-induced trauma on the retinal explants by pro-
viding a more physiologically similar microenvironment
in vitro. Additionally, the positive effect on the retina could
be due to biomechanical factors via physical interaction from
the gel that might prevent retinal folds and keep the explants
under tension. This is a factor that previously has been showed
to favorably affect retinas in vitro [44].
PEG gel elicits reactions similar to the control retinas with
comparable changes in the cytoarchitecture but with earlier,
more intense TUNEL labeling, consistent with previous
in vivo findings [38]. In the retinal explant cultures with the
longest duration (10 DIV) there was a decrease in the amount
of apoptotic cells observed at earlier time points. This may be
due to a loss of viable cells as cell death occurred earlier than
for Healaflow® and standard conditions, indicating a stronger
adverse reaction to these gels than what is caused by the
culture procedure.
Bio-Alcamid® caused severe retinal damage in vivo [37]
and negatively affected the morphology of cells and cell
layers, induced cell death and induced GFAP upregulation
very early in vitro. Some of the variability in cytoarchitecture
for retinas treated with Bio-Alcamid® might have been due to
uneven coverage of the gel. The adverse effects may in part be
influenced by uneven exposure to the medium, but cytotoxic
effects from the gel itself are likely to play a part in this
process. The explanted retinas were less affected in minor
areas that may not have been in direct contact with the gel,
although this is difficult to discern due to the loss of gel in the
preparation and sectioning procedures. This is in accordance
with previous studies that demonstrated pathological changes
in the retina in vivo, primarily in parts more likely to have
been in direct contact with the gel [37], suggesting at least in
part a toxic or immunological response. Recently, clinical use
of Bio-Alcamid® in reconstructive surgery has become in-
creasingly controversial due to late complications such as
inflammation, infection and excessive capsule formation
[45–48].
Conclusion
The retinal explant assay described in this paper has the
potential to be a useful tool for preliminary study of vitreous
substitute candidates prior to more costly andtime-
consumingin vivo testing. In addition, it may reduce the need
for laboratory animals and limit the severity of the experi-
ments from an ethical standpoint by excluding unfit sub-
stances from further testing, thereby providing refinement of
the tests. In vivo tests will still be essential before testing on
human subjects but this assay may minimize the translational
step which would prove valuable and beneficent in vetting out
unsuitable biomaterials.
A need for better vitreous substitutes still remains and more
suitable substances would be highly valuable. Healaflow®
and, to a lesser extent, PEG seem to be promising candidates
for further development and further in vivo testing of these
and similar substances is clearly indicated.
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